| 2024-07-22 | +270.7% | news | Seeking Alpha | MIRA stock rockets 627% on preclinical results for ketamine drug (update) |
| 2024-07-22 | +270.7% | news | InvestorPlace | Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today? - InvestorPlace |
| 2024-07-15 | +36.7% | analyst | TradingView | MIRA Forecast — Price Target — Prediction for 2027 - TradingView |
| 2023-09-18 | +33.2% | news | Seeking Alpha | MIRA stock soars 45% on preclinical data for THC-based drug |
| 2025-07-14 | +29.9% | news | StocksToTrade | MIRA Stocks Surge: Are They Viable Investments? - StocksToTrade |
| 2025-10-16 | +22.8% | analyst | Stocktwits | Mira Pharmaceuticals Stock Soars 70% After-Hours As Pain Drug Outperforms Morphine; Retail Sees ‘Blockbuster Drug’ In The Making - Stocktwits |
| 2025-10-16 | +22.8% | news | Benzinga | MIRA Pharmaceuticals Stock Surges Following Positive Preclinical Data - Benzinga |
| 2025-10-16 | +22.8% | news | RagingBull | MIRA Pharmaceuticals Ignites the Market: Breakthrough Pain Drug Data Fuels Massive Stock Surge - RagingBull |
| 2025-10-16 | +22.8% | news | StocksToTrade | MIRA Pharmaceuticals: Poised For A Market Shift? - StocksToTrade |
| 2025-10-16 | +22.8% | news | StocksToTrade | MIRA Pharmaceuticals Inc. (MIRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade |
| 2025-10-16 | +22.8% | analyst | ACCESS Newswire | MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain - ACCESS Newswire |
| 2025-10-16 | +22.8% | news | Blockonomi | Mira Pharmaceuticals (MIRA) Stock Rockets After Pain Drug Tops Morphine in Trials - Blockonomi |
| 2025-10-16 | +22.8% | earnings | Benzinga | Dow Surges Over 100 Points; Charles Schwab Posts Upbeat Earnings - Benzinga |
| 2025-10-16 | +22.8% | news | Benzinga | Why J.B. Hunt Transport Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket - Benzinga |
| 2025-10-16 | +22.8% | analyst | parameter.io | Mira Pharma (MIRA) Stock Surges as Pain Drug Outperforms Morphine in Tests - parameter.io |
| 2023-08-04 | -16.2% | earnings | MarketBeat | MIRA Pharmaceuticals (MIRA) Earnings Date and Reports 2026 - MarketBeat |
| 2024-01-29 | -14.6% | news | Seeking Alpha | IPO Roundup: Amer Sports, FibroBiologics, and more |
| 2026-03-23 | +13.4% | news | ACCESS Newswire | MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies |
| 2026-03-23 | +13.4% | news | Investing.com | Mira Pharmaceuticals reports preclinical results for Mira-55 with no observed THC- or rimonabant-like CNS side effects - Investing.com |
| 2026-03-23 | +13.4% | news | Stock Titan | MIRA pain drug showed morphine-like relief without THC-like effects - Stock Titan |
| 2026-03-23 | +13.4% | news | ACCESS Newswire | MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies - ACCESS Newswire |
| 2026-03-23 | +13.4% | news | Benzinga | 12 Health Care Stocks Moving In Monday's Intraday Session - Firefly Neuroscience (NASDAQ:AIFF), Allogene - Benzinga |
| 2025-04-23 | +11.9% | news | Seeking Alpha | MIRA Pharmaceuticals reports positive in vitro drug release data for topical Ketamir-2 |
| 2023-12-18 | -11.2% | news | Seeking Alpha | MIRA Pharmaceuticals files to sell up to 1.7M shares for holders |
| 2023-12-18 | -11.2% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-03-04 | +11.1% | analyst | Stock Titan | Can This Novel Ketamine Analog Outperform Gabapentin? MIRA's Neuropathic Pain Drug Enters Clinical Trials - Stock Titan |
| 2024-08-13 | -10.5% | legal | Seeking Alpha | MIRA Pharmaceuticals files $100M mixed securities shelf |
| 2025-04-24 | +10.1% | news | Stock Titan | Mira Pharma Stock Price, News & Analysis - Stock Titan |
| 2026-04-06 | -7.7% | analyst | MSN | Mira Pharmaceuticals Stock Soars 70% After-Hours As Pain Drug Outperforms Morphine; Retail Sees ‘Blockbuster Drug’ In The Making - MSN |
| 2026-04-23 | -7.5% | earnings | UBND thành phố Hải Phòng | Should I buy MIRA Pharmaceuticals (MIRA) stock right now | Q3 2025: EPS Exceeds Expectations - Margin of Safety - UBND thành phố Hải Phòng |
| 2025-07-03 | -7.3% | news | StocksToTrade | Can MIRA’s Stock Defy Gravity? - StocksToTrade |
| 2025-04-16 | +6.8% | news | Yahoo Finance | EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study - Yahoo Finance |
| 2025-03-24 | -6.7% | M&A | Seeking Alpha | MIRA Pharmaceuticals signs LOI to acquire SKNY Pharmaceuticals |
| 2025-03-24 | -6.7% | M&A | Yahoo Finance | EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug - Yahoo Finance |
| 2025-03-24 | -6.7% | news | Fierce Biotech | Mira seeks to buy Skny for its preclinical obesity, smoking cessation asset - Fierce Biotech |
| 2025-03-24 | -6.7% | M&A | Investing.com UK | MIRA Pharmaceuticals to acquire SKNY for obesity, smoking therapy By Investing.com - Investing.com UK |
| 2024-08-26 | +6.0% | news | Yahoo Finance | Midday stock movers: Temu Parent, Planet Fitness, MIRA Pharmaceuticals - Yahoo Finance |
| 2025-07-09 | +5.3% | earnings | MarketBeat | MIRA Pharmaceuticals (MIRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat |
| 2026-03-03 | -5.2% | news | Stock Titan | MIRA Pharmaceuticals (NASDAQ: MIRA) finishes Ketamir-2 Phase 1 dosing with encouraging safety - Stock Titan |
| 2024-09-26 | +5.2% | news | intelligentinvestor.com.au | MIRA Pharmaceuticals (NASDAQ: MIRA) - Share Price - intelligentinvestor.com.au |
| 2026-04-22 | -5.2% | earnings | Cổng thông tin điện tử Tỉnh Sơn La | Should I buy MIRA Pharmaceuticals (MIRA) stock right now | Q3 2025: EPS Exceeds Expectations - Price Target - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-04-22 | -5.2% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | MIRA Pharmaceuticals (MIRA) Top Loser | Q3 2025: Profit Surprises - P/B Ratio - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-03-04 | -5.0% | news | ACCESS Newswire | MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2 |
| 2025-05-08 | +4.6% | M&A | Seeking Alpha | MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M |
| 2025-05-08 | +4.6% | M&A | Yahoo Finance | EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million - Yahoo Finance |
| 2025-05-08 | +4.6% | M&A | Investing.com | MIRA Pharmaceuticals to acquire SKNY in strategic move - Investing.com |
| 2025-04-01 | -4.2% | news | Investing.com UK | MIRA Pharmaceuticals begins Phase 1 trial for pain treatment By Investing.com - Investing.com UK |
| 2026-02-02 | -3.7% | news | Stock Titan | Ketamir-2 trial progress and pipeline update at MIRA (NASDAQ: MIRA) - Stock Titan |
| 2025-05-30 | +3.3% | news | Intellectia AI | MIRA Forecast — Price Prediction for 2026. Should I Buy MIRA? - Intellectia AI |
| 2025-06-30 | -3.3% | M&A | Yahoo Finance | EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study - Yahoo Finance |
| 2023-08-05 | +3.1% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for MIRA Pharmaceuticals, Inc. (MIRA) - Zacks Investment Research |
| 2023-08-05 | +3.1% | news | Zacks Investment Research | Should I buy MIRA Pharmaceuticals, Inc. (MIRA) - Zacks Investment Research |
| 2023-08-05 | +3.1% | news | TradingView | MIRA Pharmaceuticals, Inc. Financial Statements – NASDAQ:MIRA - TradingView |
| 2026-04-01 | +2.9% | executive | Stock Titan | MIRA Pharmaceuticals (MIRA) CEO granted 83,500 RSUs - Stock Titan |
| 2025-04-11 | +2.7% | news | Investing.com | Mira Pharmaceuticals faces Nasdaq delisting over equity - Investing.com |
| 2023-08-09 | -2.2% | news | The Business Journals | Baltimore's MIRA Pharmaceuticals raises $8.9 million from IPO - The Business Journals |
| 2025-09-30 | -1.5% | M&A | Stock Titan | 30% Weight Loss: MIRA Pharma Acquires Novel Obesity Drug SKNY-1 That Also Treats Nicotine Addiction - Stock Titan |
| 2026-02-03 | +1.3% | news | ACCESS Newswire | MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study |
| 2026-02-08 | -1.3% | legal | Market Exclusive | Weekly Roundup on the Cannabis Sector & Psychedelic Sector |
| 2026-03-24 | -0.7% | news | Benzinga | 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga |
| 2023-10-03 | +0.6% | news | TradingView | Technical Analysis of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - TradingView |
| 2025-01-05 | -0.6% | news | Yahoo Finance | Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation - Yahoo Finance |
| 2023-09-30 | +0.5% | news | TradingView | MIRA Pharmaceuticals, Inc. News — NASDAQ:MIRA - TradingView |
| 2023-08-26 | -0.3% | news | Seeking Alpha | Stocks To Watch: Eyes On Treasury Yields, China EV Names, And Lululemon |
| 2023-09-04 | -0.2% | news | ChartMill | MIRA Stock Price, Quote & Chart | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill |
| 2023-08-03 | — | news | Seeking Alpha | Mira Pharmaceuticals stock ends debut session 6% higher |
| 2023-08-03 | — | news | Seeking Alpha | MIRA Pharmaceuticals prices ~$9M equity offering |
| 2023-08-03 | — | news | TradingView | MIRA Stock Price and Chart — NASDAQ:MIRA - TradingView |